ES2188584T3 - Derivados heterociclicos de amina. - Google Patents

Derivados heterociclicos de amina.

Info

Publication number
ES2188584T3
ES2188584T3 ES92921695T ES92921695T ES2188584T3 ES 2188584 T3 ES2188584 T3 ES 2188584T3 ES 92921695 T ES92921695 T ES 92921695T ES 92921695 T ES92921695 T ES 92921695T ES 2188584 T3 ES2188584 T3 ES 2188584T3
Authority
ES
Spain
Prior art keywords
heterociclical
amina
derivatives
compounds
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92921695T
Other languages
English (en)
Inventor
Anabella Villalobos
Arthur Adam Nagel
Yuhpyng Liang Chen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai Co Ltd
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Application granted granted Critical
Publication of ES2188584T3 publication Critical patent/ES2188584T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)

Abstract

COMPUESTOS DE LA FORMULA (I) EN LA QUE R1, R2, R7, R8, X, Y, M Y L SON COMO SE DEFINE MAS ABAJO. LOS COMPUESTOS DE LA FORMULA (I) SON INHIBIDORES DE COLINESTERASA Y SON UTILES EN MEJORAR LA MEMORIA DE PACIENTES QUE SUFREN DE DEMENCIA Y MAL DE ALZHEIMER.
ES92921695T 1991-03-28 1992-03-09 Derivados heterociclicos de amina. Expired - Lifetime ES2188584T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US67691891A 1991-03-28 1991-03-28

Publications (1)

Publication Number Publication Date
ES2188584T3 true ES2188584T3 (es) 2003-07-01

Family

ID=24716559

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92921695T Expired - Lifetime ES2188584T3 (es) 1991-03-28 1992-03-09 Derivados heterociclicos de amina.

Country Status (29)

Country Link
EP (1) EP0646115B1 (es)
JP (3) JP2659107B2 (es)
KR (1) KR0179054B1 (es)
CN (1) CN1044242C (es)
AT (1) ATE231505T1 (es)
AU (2) AU658194B2 (es)
BR (1) BR9205811A (es)
CA (2) CA2195129C (es)
CZ (1) CZ289756B6 (es)
DE (1) DE69232907T2 (es)
DK (1) DK0646115T3 (es)
EG (1) EG20281A (es)
ES (1) ES2188584T3 (es)
FI (1) FI934223L (es)
HU (1) HU225047B1 (es)
IE (1) IE920980A1 (es)
IL (3) IL116122A (es)
MX (1) MX9201419A (es)
MY (1) MY108885A (es)
NO (1) NO304071B1 (es)
NZ (3) NZ248946A (es)
PL (3) PL170567B1 (es)
PT (1) PT100300B (es)
RU (1) RU2119920C1 (es)
SG (1) SG49055A1 (es)
UA (1) UA45944C2 (es)
WO (1) WO1992017475A1 (es)
YU (1) YU31392A (es)
ZA (1) ZA922239B (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750542A (en) 1993-09-28 1998-05-12 Pfizer Benzisoxazole and benzisothizole derivatives as cholinesterase inhibitors
CA2116117A1 (en) * 1991-08-22 1993-03-04 Hiroyuki Sueoka Benzisoxazole compound and use thereof
EP0535496A1 (en) * 1991-09-25 1993-04-07 Hoechst-Roussel Pharmaceuticals Incorporated (1-Indanon-2yl)methylpiperidines, intermediates and a process for their preparation and their use as medicaments
US5494908A (en) * 1992-11-23 1996-02-27 Hoechst-Roussel Pharmaceutical Incorporated Substituted 3-(aminoalkylamino)-1,2-benzisoxazoles and related compounds
DE69332691T2 (de) * 1992-11-23 2003-12-18 Aventis Pharmaceuticals Inc., Cincinnati Substituierte 3-(aminoalkylamino)-1,2-benzisoxazole und verwandte verbindungen
GB9305623D0 (en) * 1993-03-18 1993-05-05 Merck Sharp & Dohme Therapeutic agents
DE69532641T2 (de) * 1994-10-26 2004-08-05 Pfizer Inc. Verfahren und zwischenprodukte zur herstellung von 5,7-dihydro-3-(2 1-benzylpiperidin-4-yl ethyl)-6h-pyrrolo-(4,5-f)-1,2-benzisoxazol-6-on
JPH11500123A (ja) * 1995-02-15 1999-01-06 ファルマシア・アンド・アップジョン・カンパニー ＣＮＳおよび心臓病の治療のためのイミダゾ［１，２−ａ］ピリジン類
KR19980703192A (ko) * 1995-03-22 1998-10-15 우에하라아끼라 티아졸 유도체
JP3057763B2 (ja) * 1995-06-06 2000-07-04 ヘキスト・マリオン・ルセル・インコーポレイテツド 抗精神病薬としてのベンゾイソオキサゾール及びインダゾール誘導体
JPH09124643A (ja) * 1995-08-14 1997-05-13 Bristol Myers Squibb Co 抗うつ作用を有する１−アリールアルキル−４−（アルコキシピリジニル）−又は４−（アルコキシピリミジニル）ピペラジン誘導体
US5916902A (en) * 1995-09-13 1999-06-29 Pfizer Inc. Processes and intermediates for preparing 5, 7-dihydro-3- 2-(1-benzylpiperidin-4-yl)ethyl-!6H-pyrrolo- 4, 5-F!-1, 2-benzisoxazol-6-one
US5998415A (en) * 1995-11-02 1999-12-07 Merck Sharp & Dohme Ltd. Bicyclic heteroaryl-alkylene-(homo)piperazinones and thione analogues thereof, their preparation, and their use of as selective agonists of 5-HT1 -like receptors
FR2751412B3 (fr) * 1996-07-17 1998-09-25 Valbiofrance Methodes de diagnostic in vitro de maladies neurodegeneratives et trousses pour la mise en oeuvre de ces methodes
US6013654A (en) * 1997-08-14 2000-01-11 Pharmacia & Upjohn Company Imidazo[1,2-A]pyridines for the treatment of CNS and cardiac diseases
EP0976404A3 (en) * 1998-07-30 2001-06-27 Pfizer Products Inc. A pharmaceutical composition for the prevention and treatment of diseases of cognitive dysfunction in a mammal
EP1604653A1 (en) 1998-09-30 2005-12-14 Takeda Pharmaceutical Company Limited Acetylcholinesterase inhibitors for improving excretory potency of urinary bladder
EP1050303A3 (en) * 1999-04-27 2003-01-15 Pfizer Products Inc. Methods and compositions for treating age-related behavioral disorders in companion animals
US6951873B1 (en) 1999-04-27 2005-10-04 Pfizer Inc. Methods for treating age-related behavioral disorders in companion animals
AU767726B2 (en) * 1999-04-30 2003-11-20 Pfizer Products Inc. Radiotracers for in vivo study of acetylcholinesterase and Alzheimer's disease
GB9914486D0 (en) 1999-06-21 1999-08-18 Smithkline Beecham Plc Medicaments
GB9917408D0 (en) 1999-07-23 1999-09-22 Smithkline Beecham Plc Compounds
GB9917406D0 (en) 1999-07-23 1999-09-22 Smithkline Beecham Plc Compounds
DK1209151T3 (da) 1999-09-01 2007-08-20 Eisai R&D Man Co Ltd 4-substituerede piperidinderivativer
DE60139781D1 (de) 2000-06-21 2009-10-15 Eisai R&D Man Co Ltd 4-substituierte piperidinverbindung
EP1436297B1 (en) * 2001-10-17 2007-04-25 Ciba Specialty Chemicals Holding Inc. Photoactivable nitrogen bases
US7226915B2 (en) * 2003-05-15 2007-06-05 Hoffmann-La Roche Inc. Diaminopyrroloquinazolines compounds as protein tyrosine phosphatase inhibitors
DE602004010299T2 (de) * 2003-12-22 2008-09-18 Memory Pharmaceuticals Corp. Indole, 1h-indazole, 1,2-benzisoxazole und 1,2-benzisothiazole und deren herstellung und anwendungen
EP1609783A1 (en) * 2004-06-17 2005-12-28 Neuropharma S.A.U. Marine compounds with calcium channel blocking properties for Alzheimer's disease treatment
DE102005038947A1 (de) * 2005-05-18 2006-11-30 Grünenthal GmbH Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln
JP2008545008A (ja) * 2005-06-30 2008-12-11 プロシディオン・リミテッド Ｇｐｃｒアゴニスト
GB0519879D0 (en) 2005-09-30 2005-11-09 Astrazeneca Ab Chemical process
JPWO2007126041A1 (ja) 2006-04-28 2009-09-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 ベンゾイソオキサゾール化合物
PE20090319A1 (es) 2007-06-01 2009-03-27 Schering Corp Moduladores de gamma secretasa
EP2285783B1 (en) 2008-04-29 2014-05-21 Boehringer Ingelheim International GmbH Indazole compounds as ccr1 receptor antagonists
WO2009137338A1 (en) 2008-05-06 2009-11-12 Boehringer Ingelheim International Gmbh Pyrazole compounds as ccr1 antagonists
JP5507567B2 (ja) 2008-09-26 2014-05-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ１受容体拮抗薬としてのアザインダゾール化合物
CN102232078B (zh) * 2008-12-12 2014-07-16 埃科特莱茵药品有限公司 5-氨基-2-(1-羟基-乙基)-四氢吡喃衍生物
PL2491028T3 (pl) 2009-10-21 2014-05-30 Boehringer Ingelheim Int Związki indazolowe i pirazolopirydynowe jako antagoniści receptora CCR1
US8927550B2 (en) 2009-10-27 2015-01-06 Boehringer Ingelheim International Gmbh Heterocyclic compounds as CCR1 receptor antagonists
US20110212928A1 (en) 2010-02-09 2011-09-01 The Johns Hopkins University Methods and compositions for improving cognitive function
JP5793182B2 (ja) 2010-04-30 2015-10-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｃｒ１受容体アンタゴニストとしてのアザインダゾールアミド化合物
US8546442B2 (en) 2010-12-23 2013-10-01 Boehringer Ingelheim International Gmbh Pyrazolopiperidine compounds as CCR1 receptor antagonists
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
US10179779B2 (en) 2012-11-21 2019-01-15 Raqualia Pharma Inc. Polymorph forms
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
EP2968220B1 (en) 2013-03-15 2021-05-05 Agenebio, Inc. Methods and compositions for improving cognitive function
NZ738682A (en) 2015-05-22 2022-01-28 Agenebio Inc Extended release pharmaceutical compositions of levetiracetam
RU2638155C1 (ru) * 2016-02-29 2017-12-12 Общество С Ограниченной Ответственностью "Сай Фарма" Производные бензо[d]изоксазола и их применение
JP2024529068A (ja) * 2021-08-10 2024-08-01 江蘇恒瑞医薬股▲ふん▼有限公司 スルファミド誘導体、その調製方法及びその医薬的使用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3488353A (en) 1967-05-29 1970-01-06 Sterling Drug Inc New 1-((2-azaindolyl)-lower-alkyl) 4-substituted-piperazines
JPS51136666A (en) * 1975-05-19 1976-11-26 Dainippon Pharmaceut Co Ltd Process for preparing 3-aminoalkyl-1,2-benzisoxazole derivatives.
US4396770A (en) * 1982-04-09 1983-08-02 Hoechst-Roussel Pharmaceuticals Inc. 1-[3-(6-Fluoro-1,2-benzisoxazol-3-yl)propyl]-4-hydroxy-4-phenylpiperidines
IL66866A (en) * 1982-04-09 1987-08-31 Hoechst Roussel Pharma 1-(3-(6-fluoro-1,2-benzisoxazol-3-yl)propyl)-4-(substituted)-piperazines and-piperidines,a process for the preparation thereof,and pharmaceutical compositions containing them
US4489075A (en) * 1982-05-15 1984-12-18 Pfizer Inc. Cyclic sulfonamidoalkyl substituted 4-piperidinoquinazoline cardiac stimulants
PH22302A (en) * 1985-02-11 1988-07-22 Fujisawa Pharmaceutical Co Piperidine compounds
DK623586A (da) * 1985-12-27 1987-06-28 Eisai Co Ltd Piperidinderivater eller salte deraf og farmaceutiske kompositioner indeholdende forbindelserne
JPS63234065A (ja) * 1987-03-23 1988-09-29 Mitsubishi Rayon Co Ltd 包接能を有する高分子組成物
JPH0657707B2 (ja) * 1987-05-25 1994-08-03 吉富製薬株式会社 ピペリジン化合物
FI95572C (fi) * 1987-06-22 1996-02-26 Eisai Co Ltd Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
US4980365A (en) * 1987-07-13 1990-12-25 Hoechst-Roussel Pharmaceuticals Inc. N-substituted-5,6-dimethoxy-1,2-benzisoxazole-3-propanamine and related compounds as analgesic and hypotensive agents
ATE87918T1 (de) * 1988-02-19 1993-04-15 Lilly Co Eli Tetrazolverbindungen als antagonisten der excitatorischen aminosaeurerezeptoren.
JPH0283375A (ja) * 1988-09-21 1990-03-23 Dainippon Pharmaceut Co Ltd ２−置換ピペラジニル−２−（１，２−ベンズイソキサゾール−３−イル）酢酸誘導体
FR2654104B1 (fr) * 1989-11-07 1992-01-03 Adir Nouveaux derives du 1,2-benzisoxazole, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
ATE201669T1 (de) * 1991-04-17 2001-06-15 Upjohn Co Substituierte (s)-3-phenylpiperidin derivate, deren herstellung und deren verwendung als dopamin autorezeptor antagonisten

Also Published As

Publication number Publication date
ZA922239B (en) 1993-09-27
IL116122A (en) 1998-10-30
FI934223A0 (fi) 1993-09-27
PT100300B (pt) 1999-09-30
DE69232907D1 (de) 2003-02-27
AU674477B2 (en) 1996-12-19
CN1065267A (zh) 1992-10-14
YU31392A (sh) 1994-12-28
JP2659107B2 (ja) 1997-09-30
CZ395892A3 (en) 1994-04-13
JP2000154185A (ja) 2000-06-06
ATE231505T1 (de) 2003-02-15
CZ289756B6 (cs) 2002-04-17
HUT68357A (en) 1995-06-28
KR0179054B1 (en) 1999-03-20
IL116122A0 (en) 1996-01-31
AU658194B2 (en) 1995-04-06
CA2195129C (en) 2002-09-10
IL101327A (en) 1998-06-15
CA2195129A1 (en) 1992-09-29
AU1878292A (en) 1992-11-02
HU9302733D0 (en) 1993-12-28
IL101327A0 (en) 1992-11-15
MX9201419A (es) 1992-10-01
RU2119920C1 (ru) 1998-10-10
SG49055A1 (en) 1998-05-18
JPH06500794A (ja) 1994-01-27
PL171915B1 (pl) 1997-06-30
CN1044242C (zh) 1999-07-21
PL170567B1 (pl) 1997-01-31
UA45944C2 (uk) 2002-05-15
NO933445D0 (no) 1993-09-27
AU2178895A (en) 1995-09-07
EP0646115A1 (en) 1995-04-05
JPH10158264A (ja) 1998-06-16
HU225047B1 (en) 2006-05-29
FI934223A7 (fi) 1993-09-27
PT100300A (pt) 1993-08-31
CA2107105C (en) 2003-10-07
BR9205811A (pt) 1994-06-28
CA2107105A1 (en) 1992-09-29
IE920980A1 (en) 1992-10-07
NZ248946A (en) 1995-04-27
NO933445L (no) 1993-09-27
NZ242151A (en) 1994-10-26
WO1992017475A1 (en) 1992-10-15
EG20281A (en) 1998-07-30
DE69232907T2 (de) 2003-05-15
MY108885A (en) 1996-11-30
NO304071B1 (no) 1998-10-19
DK0646115T3 (da) 2003-04-22
NZ250987A (en) 1997-06-24
PL171914B1 (pl) 1997-06-30
JP3051076B2 (ja) 2000-06-12
FI934223L (fi) 1993-09-27
EP0646115B1 (en) 2003-01-22

Similar Documents

Publication Publication Date Title
MY108885A (en) Heterocyclic-cyclic amine derivatives.
MX9700557A (es) Dihidrobenzofuranos.
ES2193137T3 (es) Heteroaril aminas como nuevos inhibidors de acetilcolinesterasa.
ES2040838T3 (es) Compuestos piperazinil-heterociclicos.
ES2127946T3 (es) Antagonistas de neurocinina diazabiciclica.
ES2146741T3 (es) Derivados de rapamicina utiles como inmunosupresores.
MX9300498A (es) Derivados de n-sulfonil-2-oxo-indol, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
AR029216A1 (es) Compuestos inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias; composicion farmaceutica y procedimiento de tratamiento
ES2126661T3 (es) Pirazoles que tienen actividad antagonista de crf.
ES2064667T3 (es) Derivados de 3-aminopiperidina y heterociclos relacionados que contienen nitrogeno.
TR199901905T2 (xx) 2-(P�rin-9-il)-tetrahidrofuran-3,4-diol t�revleri.
TR199801255T2 (xx) Vitronektin resept�r antagonistleri.
ES2062374T3 (es) Heteroarilpiperazinas, agentes antipsicoticos.
ES2113368T3 (es) Antagonistas de serotonina.
ES2183331T3 (es) Inhibidores de sulfamida-metaloproteasa.
ATE180781T1 (de) Kristallines tiagabinehydrochlorid-monohydrat, seine herstellung und verwendung
ES2123873T3 (es) Pirrolocarbazol.
ES2160602T3 (es) Derivados de quinolona y acridinona para el tratamiento de la incontinencia urinaria.
ES2110260T3 (es) Androstenonas.
MX9700959A (es) Derivados de becimidazol que tienen actividad dopaminergica.
MX9700854A (es) Derivados de azabicicloheptano n-substituidos utiles como neurolepticos.
AR006084A1 (es) Aminofeniluracilos substituidos y empleo de los mismos para la lucha contra las plantas indeseables
MX9301863A (es) Morfolin y tiomorfolin 4-ilamidas
ES2149193T3 (es) Compuestos heterociclicos sustituidos con alquilo.
MX9708510A (es) Tetralinas.